Target Price | $34.29 |
Price | $24.11 |
Potential |
42.21%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Catalyst Pharmaceuticals, Inc. 2026 .
The average Catalyst Pharmaceuticals, Inc. target price is $34.29.
This is
42.21%
register free of charge
$40.00
65.91%
register free of charge
$32.00
32.73%
register free of charge
|
|
A rating was issued by 7 analysts: 7 Analysts recommend Catalyst Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Catalyst Pharmaceuticals, Inc. stock has an average upside potential 2026 of
42.21%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 491.73 | 555.14 |
23.49% | 12.90% | |
EBITDA Margin | 47.42% | 36.11% |
57.41% | 23.85% | |
Net Margin | 32.20% | 31.03% |
68.39% | 3.64% |
7 Analysts have issued a sales forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Catalyst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Catalyst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.31 | 1.43 |
107.94% | 9.16% | |
P/E | 16.92 | |
EV/Sales | 4.35 |
6 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast for earnings per share. The average Catalyst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Catalyst Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jan 09 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 09 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.